Alec W. Gross, Ph.D. - Publications
Affiliations: | 2002 | Brandeis University, Waltham, MA, United States |
Area:
Oncology, Cell Biology, GeneticsYear | Citation | Score | |||
---|---|---|---|---|---|
2006 | Lu X, Gross AW, Lodish HF. Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. The Journal of Biological Chemistry. 281: 7002-11. PMID 16414957 DOI: 10.1074/Jbc.M512638200 | 0.312 | |||
2004 | Ji Y, Gross AW, Zhang X, Ren R. The Abl Carboxyl Terminal Region Is Required for the Induction of Acute Lymphoblastic Leukemia by V-Abl but Not for the Induction of Myeloproliferative Disease by BCR/ABL or V-Abl. Blood. 104: 2969-2969. DOI: 10.1182/Blood.V104.11.2969.2969 | 0.634 | |||
2003 | Dinulescu DM, Wood LJ, Shen L, Loriaux M, Corless CL, Gross AW, Ren R, Deininger MW, Druker BJ. c-CBL is not required for leukemia induction by Bcr-Abl in mice. Oncogene. 22: 8852-60. PMID 14654781 DOI: 10.1038/Sj.Onc.1206892 | 0.658 | |||
2001 | Zhang X, Subrahmanyam R, Wong R, Gross AW, Ren R. The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Molecular and Cellular Biology. 21: 840-53. PMID 11154271 DOI: 10.1128/Mcb.21.3.840-853.2001 | 0.566 | |||
2000 | Gross AW, Ren R. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells. Oncogene. 19: 6286-96. PMID 11175343 DOI: 10.1038/Sj.Onc.1204023 | 0.626 | |||
1999 | Gross AW, Zhang X, Ren R. Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Molecular and Cellular Biology. 19: 6918-28. PMID 10490629 DOI: 10.1128/Mcb.19.10.6918 | 0.699 | |||
Show low-probability matches. |